Non-small-cell lung cancer
Conditions
Interventions
Group A:Surufatinib
Sponsors
Guangxi Medical University Affiliated Tumor Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years; 2. Pathologically diagnosed late (stage IV), EGFR wild type; 3. ECOG PS 0-1; 4. Previous drug treatment consisted of a platinum-based chemotherapy regimen (> 1 chemotherapy regimen) for relapse or failure of treatment; 5. Sign the inform consent form with good compliance.
Exclusion criteria
Exclusion criteria: 1. Patients who had previously received Surufatinib treatment were excluded; 2. Patients with active brain metastasis, carcinomatous meningitis, or spinal compression, or disease of brain or pia mater according to the screening test, imaging, CT or MRI tests (patients who have completed the treatment and in a stable condition 21 days before screening could be included, but brain MRI, CT or venography is required to confirm that there are no brain hemorrhage symptoms); 3. Patients with uncontrollable hypertension (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg, despite optimal drug therapy); 4. Patients with with grade II myocardial ischemia or myocardial infarction, poor control of arrhythmias (including QTc interval male >= 450 ms, female >= 470 ms); 5. According to NYHA standard, grade III ~ IV heart failure, or cardiac color Doppler ultrasound examination showed left ventricular ejection fraction (LVEF) = ++ or verifies that the 24-h urine protein quantitation >= 1.0 g; 7. Onditions determined by investigators to possibly affect the clinical study or determination of the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival, PFS; | — |
Countries
China
Contacts
Public ContactYu Qitao
Guangxi Medical University Affiliated Tumor Hospital
Outcome results
None listed